Pettit Michael
Clinical Pharmacy Unit, Royal Sussex Country Hospital, University of Brighton, Eastern Road, Brighton, BN2 5BE, UK.
Pharm World Sci. 2005 Dec;27(6):432-5. doi: 10.1007/s11096-005-4798-7.
AIM OF THE REVIEW AND METHODS: This review brings together information on the treatment of gastroesophageal reflux disease. Published manuscripts were identified from Medline. The articles were then screened for relevance prior to inclusion in the review.
Up to 40% of people in Western countries are estimated to regularly experience heartburn, the most characteristic symptom of gastroesophageal reflux disease (GERD). Treatment options available for GERD range from over-the-counter (OTC) antacids to proton pump inhibitors (PPIs) and anti-reflux surgery. Many patients self-medicate with OTC medications such as antacids and low-dose histamine H2-receptor antagonists (H2RA) to relieve episodic or food-related symptoms of GERD, and may not seek medical advice unless symptoms persist or worsen. However, GERD is a chronic disease that frequently affects health-related quality of life and, if not properly managed, the complications of GERD may include erosive oesophagitis (EO), Barrett's oesophagus and adenocarcinoma. Adequate control of acid secretion is key to the successful treatment of the condition. OTC medications provide effective symptom relief to about one quarter of patients suffering from GERD. H2RAs can also provide effective symptomatic relief, particularly in patients with milder GERD, but become less-effective over time. PPIs are the agents of choice for the suppression of gastric acid production and have become the mainstay of therapy for acid-related diseases. PPIs produce significantly faster and more complete symptomatic relief, significantly faster and more complete healing of erosive GERD compared with H2RAs and are also significantly more effective at preventing relapse of EO. There are a number of existing guidelines for the treatment of GERD. Recommendation for initial therapy consist of general measures, such as lifestyle advice in combination with antacids and/or alginates. When general measures fail, the next step is empirical therapy. Two options exist for the expirical treatment of GERD, so-called "step-up" or "step-down" therapy. There are no clear data to support either treatment strategy as a universal approach to all patients; consequently, physicians must always choose the course best suited to the individual patient.
综述目的及方法:本综述汇集了有关胃食管反流病治疗的信息。从医学数据库(Medline)中检索已发表的手稿。在纳入综述之前,先对文章进行相关性筛选。
据估计,西方国家高达40%的人经常经历烧心,这是胃食管反流病(GERD)最典型的症状。GERD的治疗选择范围从非处方(OTC)抗酸剂到质子泵抑制剂(PPI)和抗反流手术。许多患者自行使用非处方药物,如抗酸剂和低剂量组胺H2受体拮抗剂(H2RA)来缓解GERD的发作性或与食物相关的症状,除非症状持续或加重,否则可能不会寻求医疗建议。然而,GERD是一种慢性疾病,经常影响与健康相关的生活质量,如果管理不当,GERD的并发症可能包括糜烂性食管炎(EO)、巴雷特食管和腺癌。充分控制胃酸分泌是成功治疗该病的关键。非处方药物能为约四分之一的GERD患者有效缓解症状。H2RA也能有效缓解症状,尤其是在症状较轻的GERD患者中,但随着时间推移效果会变差。PPI是抑制胃酸分泌的首选药物,已成为治疗酸相关疾病的主要手段。与H2RA相比,PPI能显著更快、更完全地缓解症状,能显著更快、更完全地治愈糜烂性GERD,在预防EO复发方面也显著更有效。现有多项GERD治疗指南。初始治疗的建议包括一般措施,如生活方式建议并联合抗酸剂和/或藻酸盐。当一般措施无效时,下一步是经验性治疗。GERD经验性治疗有两种选择,即所谓的“逐步升级”或“逐步降级”疗法。没有明确数据支持将这两种治疗策略作为适用于所有患者的通用方法;因此,医生必须始终选择最适合个体患者的治疗方案。